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Value of Delayed Hypointensity and Delayed
Enhancing Rim in Magnetic Resonance Imaging
Diagnosis of Small Hepatocellular Carcinoma
in the Cirrhotic Liver
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Purpose: To determine the diagnostic utility of delayed
hypointensity and delayed enhancing rim on magnetic
resonance imaging (MRI) as indicators of hepatocellular
carcinoma (HCC) in arterially enhancing nodules 5 cm
in the cirrhotic liver and determine the features that best
predict HCC.
Materials and Methods: Gadolinium-enhanced MRI stud-
ies performed from January 2001 to December 2004 in
patients with cirrhosis were evaluated for arterially
enhancing nodules measuring 5 cm. Verification was via
explant correlation, biopsy, or imaging follow-up. Sensi-
tivity and specificity of diagnostic features of HCC were
calculated. Features predictive of HCC were determined
using the Generalized Estimating Equation approach.
Results: In all, 116 arterially enhancing nodules were
identified in 80 patients (<2 cm: n ¼ 79, 2–5 cm n ¼ 37).
Sensitivity and specificity of delayed hypointensity for
HCC measuring 5 cm, 2–5 cm, and <2 cm were 0.54 (40
of 74) and 0.86 (36 of 42); 0.72 (23 of 32) and 0.80 (4 of
5); and 0.41 (17 of 42) and 0.87 (32 of 37). For the
delayed enhancing rim sensitivity and specificity were
0.64 (47 of 74) and 0.86 (36 of 42); 0.75 (24 of 32) and
1.0 (5 of 5); and 0.55 (23 of 42) and 0.83 (31 of 37),
respectively. Lesion size (2 cm) and delayed enhancing
rim, as main features and their interaction, were the most
significant predictors of HCC.
Conclusion: Delayed hypointensity and enhancing rim
improve the specificity of diagnosis of HCC of all sizes but
are seen less frequently in small (<2 cm) HCC. Nodule
size (2 cm) and delayed enhancing rim are the strongest
predictors of HCC.
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HEPATOCELLULAR CARCINOMA (HCC) is the most
common primary hepatic malignancy, with an inci-
dence in the United States of 2.4 per 100,000 per
year (1). Liver transplantation can markedly increase
survival in patients with HCC if criteria for early stag-
ing are met (2,3). Current United Network of Organ
Sharing (UNOS) criteria for transplantation do not
require tissue confirmation of HCC by biopsy but rely
on imaging characterization, particularly arterial
enhancement (4). However, pretransplant image stag-
ing has been shown to be less then 50% accurate
when compared to posttransplant pathological staging
with imaging over- and understaging HCC (5).
Due to the scarcity of livers available it is imperative
to accurately characterize focal liver lesions prior to
transplantation. However, using the current UNOS
criteria of arterial blush, at a single transplant center
in the United States, 33% of patients transplanted for
HCC did not have tumor in the explant and 63% of
the misdiagnosed tumors were arterially enhancing
lesions 2 cm or smaller in diameter (6). Moreover,
studies have shown that up to 93% of lesions less
than 2 cm seen only on the arterial phase of imaging
are nonneoplastic (7–11). Thus, arterial enhancement
alone is not always specific for HCC (12).
Patients with limited HCC (TNM stage II: single HCC
2–5 cm or up to 3 HCCs, each less than 3 cm) can
undergo liver transplantation. Single small HCC
(<2 cm) can be successfully treated with resection or
ablation and are more likely to have complete
response to local therapies (13).
Hypointensity on portal venous and/or delayed
phases of gadolinium-enhanced imaging has been
reported as a specific indicator of HCC (14–16).
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However, small histologically well-differentiated ‘‘early
HCC’’ may retain some conventional liver vasculature,
and consequently not demonstrate delayed hypointen-
sity (17). Delayed enhancing rim is also a known fea-
ture of HCC (18–20). Few studies have investigated
the frequency of occurrence of delayed hypointensity
or delayed enhancing rim in HCC in the cirrhotic liver.
The purpose of this study was to determine the
diagnostic utility of delayed hypointensity and delayed
enhancing rim on MRI as indicators of HCC in arteri-
ally enhancing nodules 5 cm in the cirrhotic liver
and to determine the features that best predict HCC.
MATERIALS AND METHODS
This retrospective study was in compliance with our
Institutional Review Board (IRB) rules and the Health
Insurance Portability and Accountability Act (HIPAA).
IRB approval was obtained for the study and informed
consent waived due to its retrospective nature.
Study Population
Our hospital MRI records were searched for all adults
(18 years) with chronic liver disease who underwent
liver MRI between January 2001 and December 2004.
Changes of cirrhosis were confirmed by histology in
64 patients (43 percutaneous biopsies, 21 explants).
In 12 patients pathologic confirmation was not avail-
able; however, morphological changes of cirrhosis and
secondary portal hypertension were seen on MRI. In
the four remaining patients, biopsy demonstrated
fibrosis and inflammation without frank changes of
cirrhosis. As screening is recommended in patients
with bridging fibrosis (18) because transition from
bridging fibrosis to cirrhosis is difficult to determine
clinically, these patients were included in our study.
For inclusion, the patient must have had diagnostic
quality contrast-enhanced 3D T1-weighted gradient-
recalled echo (GRE) imaging with the arterial-domi-
nant phase ideally timed (enhancement of hepatic
arteries, slight enhancement of portal vein, and no
enhancement of hepatic veins). However, if timing was
earlier with minimal or no portal vein enhancement
(n ¼ 4), the patient was still included, as an enhanc-
ing nodule would accumulate contrast sooner than
surrounding parenchyma. Studies that showed
enhancement of the hepatic veins on the first phase of
imaging were excluded.
Patients with known HCC who underwent partial
hepatectomy or radiofrequency ablation were included
and evaluated for additional lesions. Those treated
with transarterial chemoembolization (TACE) or radia-
tion therapy were excluded as these treatments may
change the perfusion dynamics of the liver.
A total of 394 patients with cirrhosis and available
verification of MRI findings were scanned from Janu-
ary 2001 to December 2004. In all, 274 patients were
excluded because of no visualized arterially enhancing
nodule 5 cm, nine for suboptimal dynamic phase
imaging (missed arterial phase imaging n ¼ 4; non-
diagnostic study n ¼ 5), and 31 for prior therapy
(TACE n ¼ 22, radiotherapy n ¼ 9). Thus, the study
population comprised 80 patients (mean age 57 years,
range 36–78) with 116 arterially enhancing nodules
measuring 5 cm. Twenty patients were women
(mean age 59.4 years, range 36–78 years) and 60
were men (mean age 55.3 years, range 41–74 years).
Fifty-six patients had one arterially enhancing nodule,
12 had two, and 12 had three.
MRI Techniques
MR imaging was performed on a 1.5-T system (Signa;
General Electric Medical Systems, Milwaukee, WI). A
4-channel phased array receiver coil was used. T1-W
imaging included dual-echo opposed-phase (OP)/in-
phase (IP) GRE imaging (TR/TE <180/2.2–4.4 msec,
flip angle 70, slice thickness/gap 6/0 mm, matrix
256 (frequency)  160 (phase)). T2-W imaging was
performed using either a fat-suppressed respiratory-
triggered fast spin-echo (FSE) sequence (TR range/
TEeff <5000/80–100 msec, echo train length 18) (n ¼
54 patients) or a breath hold fast recovery FSE (FR-
FSE) sequence (TR range/TEeff <2500/80–100 msec,
echo train length 17) (n ¼ 26 patients), slice thick-
ness/gap 6/0 mm, matrix 256  224. A rectangular
field of view was often used to reduce the number of
phase-encoding acquisitions.
Dynamic imaging was performed before and after
intravenous injection of gadopentetate dimeglumine
(Magnevist; Bayer, Wayne, NJ) using a 3D GRE
sequence with spectral fat saturation (TR/TE 4–6/1.2
msec, flip angle 12, matrix 256–320  128–192, sec-
tion thickness 4.0 mm with 2 mm overlap). Gadopen-
tetate dimeglumine was used at a dose of 0.1 mmol/
kg (maximum dose 20 mL) administered via a power
injector in an antecubital vein at a rate of 2 mL/sec,
followed by 20 mL of normal saline flush at the same
rate. After unenhanced imaging, contrast arrival for
arterial-dominant phase imaging were timed using
automated contrast bolus detection, Smart-Prep (GE
Medical Systems). Venous and extracellular phase
images were obtained at 50–70 sec and 120–200 sec,
respectively, after the initiation of contrast injection.
Image Analysis
Studies were reviewed independently by two radiolog-
ists with 4 and 10 years experience interpreting liver
MRI on a commercially available workstation (Advant-
age Workstation; GE Medical Systems). Lesions were
preselected for review by one reader who noted the
image number of the lesion on the arterial phase of
postgadolinium imaging. If the second reviewer noted
an additional lesion then the discrepancy was
resolved by consensus (n ¼ 2). All sequences for each
study were presented to the reviewers in one setting.
Readers were blinded to the clinical MRI interpreta-
tions and final diagnosis.
Arterially enhancing nodules measuring 5 cm
were identified (Fig. 1a). Comparison to precontrast
fat-suppressed T1-weighted sequence was made to
ensure that hyperintensity was due to contrast
enhancement and subtraction imaging (arterial-phase
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minus precontrast) was occasionally performed for
lesions (n ¼ 17) with hyperintense signal on pre-
contrast imaging. For patients with multiple lesions
the three largest lesions within this size limit were
included. Both radiologists assigned a qualitative
assessment score of lesion signal intensity with respect
to the background liver as hyperintense, isointense, or
hypointense. Lesion signal intensity was recorded on
T1-W OP/IP, T2-W, and gadolinium-enhanced sequen-
ces. Any interpretation discrepancy (n ¼ 6) was
resolved by reassessment of lesion signal intensity rel-
ative to adjacent parenchyma by consensus of the two
radiologists. Other findings of rim enhancement in the
venous and/or delayed phases (Fig. 1b), and internal
lipid, identified by comparing in-phase and out-of-
phase T1-W imaging were also documented.
Verification
Verification of the identified lesions with pathology
(explant or biopsy) or follow-up MRI was essential for
inclusion. Lesions that demonstrated interval growth
of 100% diameter increase in 1 year or 50% in 6
months (21) or had pathological confirmation were
considered HCC. For classification as nonmalignant,
lesions had to have pathological proof of diagnosis or
at least 18-month MRI follow-up demonstrating sta-
bility or disappearance.
Explanted livers were cut sequentially in 5–10-mm
sections in the axial plane to match the MRI studies.
The MRI reports were reviewed at time of gross sec-
tioning to guide nodule localization. The overall mean
time between transplant and MRI was 7.2 months
(range 1–33) including 13.1 months (range 1–33) for
14 nonmalignant lesions and 4.4 months (range 1–18)
for 29 malignant lesions.
Of the 116 lesions included in the study, verification
was by biopsy for 28, explant correlation for 43, and
MRI follow-up for 45 lesions (mean 20.4, range 4–47).
Statistical Analysis
Sensitivity and specificity of delayed hypointensity
and delayed enhancing rim, as features diagnostic of
HCC, were calculated on a lesion-by-lesion basis.
Generalized Estimating Equations (GEE) (22) models
were fit with the main imaging features of HCC and
their interactions to determine the predictors of HCC.
GEE is a statistical method that fits parameters to a
generalized linear model when unknown correlation is
present. The focus of a GEE analysis is on population
level average effects rather than random effects. The
main features were: size 2 cm or larger and less than
2 cm, T2-weighted hyperintense signal, T1-weighted
hypointense signal, lipid content, delayed postcon-
trast hypointensity, and delayed enhancing rim. The
sampling took place at the patient level, with clusters
of lesions within individuals. Leaving one variable out
at a time cross-validation was used to estimate sensi-
tivity and specificity of the resulting models.
RESULTS
Of the 116 nodules included in the study, 74 (64%)
were HCC (transplant n ¼ 29, biopsy n ¼ 22, MRI fol-
low-up n ¼ 23) and 42 were nonmalignant.
Of the 42 nonmalignant arterially enhancing nod-
ules, 20 were verified at pathology (explant n ¼ 14
[12 regenerative nodules and two high-grade dys-
plastic nodules]; biopsy n ¼ 6 [two regenerative nod-
ules, two high-grade dysplastic nodules, one fibrosis,
and one focal nodular hyperplasia]) and 22 by follow-
up MRI for a minimum of 18 months (mean 27.5,
range 19–47).
Mean size of 74 HCC nodules was 2.2 cm (range
1.0–4.8 cm) and that of nonmalignant nodules 1.5 cm
(1.0–4.6 cm). 32 of 74 (43%) HCC nodules measured
2–5 cm and 42 (57%) were smaller than 2 cm. For one
patient with three nodules, evaluation of unenhanced
T1-W and T2-W signal intensity was not possible sec-
ondary to motion artifact. Of 113 nodules with diag-
nostic T2-W imaging 56 were isointense in signal rela-
tive to liver parenchyma (HCC n ¼ 25; nonmalignant
Figure 1. A 31-year-old woman with hepatitis C cirrhosis.
(a) T1-weighted volumetric 3D fat-suppressed spoiled gradi-
ent echo MR image (TR/TE, 4–6/1.2 msec flip angle 12) in
the arterial phase demonstrating a small enhancing nodule
(arrow). (b) MR images obtained in the extracellular phase
show hypointensity and a peripheral capsule.
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n ¼ 31) and 57 were hyperintense (HCC n ¼ 46; non-
malignant n ¼ 11). Internal fat was identified by demon-
strating signal loss on out-of-phase imaging compared
to in-phase and was seen in 14 nodules (HCC n ¼ 12,
nonmalignant n ¼ 2).
Lesion-based sensitivities and specificities of
delayed hypointensity and delayed enhancing rim for
HCC are shown in Table 1. For analysis, hypointen-
sity on either venous or delayed phase imaging was
considered as delayed hypointensity. Delayed hypoin-
tensity was highly specific (0.87) for arterially enhanc-
ing HCC <2 cm but only seen in 17 of 42 (40%) of
these small tumors. The 34 of 74 HCC in our study
did not demonstrate delayed hypointensity including
25/42 <2 cm and 9/32 2–5 cm HCCs (Fig. 2). The
sensitivity of delayed enhancing rim for HCC was
slightly higher than that of delayed hypointensity,
particularly for lesions <2 cm.
Four nonmalignant nodules demonstrated hypoin-
tensity on delayed phase imaging. Two of these nod-
ules demonstrated no change on MRI follow-up over
26 and 35 months. Two had biopsy follow-up yielding
one regenerative nodule and one regenerative nodule
with small cell dysplasia.
Four nonmalignant lesions had a delayed enhancing
rim. Two of these nodules were not seen on follow-up
MRI done at 19 and 21 months. One was determined
to be a high-grade dysplastic nodule at explant correla-
tion. One had biopsy follow-up yielding high-grade dys-
plastic nodule.
Two benign lesions demonstrated both hypointen-
sity and delayed enhancing rim. One lesion had
biopsy yielding dysplastic nodule. One nodule had
biopsy follow-up yielding fibrosis and 28-month MRI
follow-up that demonstrated minimal change (Fig. 3).
A GEE model fitted with the individual features of
HCC showed that delayed enhancing rim (P ¼ 0.026)
was a significant predictor of HCC (Table 2). To identify
the best individual and combinations of features pre-
dictive of HCC, the least significant features were
removed from the model (Table 3). The delayed enhanc-
ing rim and its interaction with size (2 cm) (P ¼ <2 
1016) were the best predictors of HCC (Table 3).
DISCUSSION
HCC is thought to arise in the cirrhotic liver as a
result of stepwise progression from regenerative nod-
ule to low then high-grade dysplastic nodule, to dys-
plastic nodule with microscopic HCC, to small HCC.
Imaging features reflect a shift in the dominant blood
supply of these nodules as they progress to HCC (20).
With progression to malignancy, the blood supply
shifts from portal venous to abnormal hepatic arterial
supply (neoplastic angiogenesis) resulting in arterial
enhancement (23,24). Thus, arterial hypervascularity
of a nodule is suspicious for HCC (25–27). However,
arterial enhancement, especially in nodules meas-
uring <2 cm, is nonspecific for HCC and is seen in
nonmalignant lesions (23,28).
Since most arterially enhancing lesions 2 cm are
highly likely to be HCC, current recommendations
suggest that these lesions do not require pathological
confirmation if they display imaging features typical
for HCC (arterial hypervascularity and delayed hypo-
intensity) on CT or MRI (9). Results from this study
confirm that a high proportion (86%, 32/37) of arteri-
ally enhancing nodules measuring 2–5 cm are HCC.
Arterially enhancing lesions <2cm have a lower but
still significant probability of being HCC. In this
study, 53% (42/79) of such lesions were HCC. In the
study by Marrero et al (16), 19% of arterially enhanc-
ing nodules <2 cm were HCC, and 23% (6 of 26)
in the study by Jeong et al (21). At this level of
Table 1
Sensitivity and Specificity of Delayed Hypointensity and Delayed
Enhancing Rim as Features of Arterially Enhancing HCC 5 cm
Size [cm] Parameter Sensitivity Specificity
5
Delayed hypointensity 0.54 (40/74) 0.86 (36/42)
Delayed enhancing rim 0.64 (47/74) 0.86 (36/42)
2-5
Delayed hypointensity 0.72 (23/32) 0.80 (4/5)
Delayed enhancing rim 0.75 (24/32) 1.00 (5/5)
<2
Delayed hypointensity 0.41 (17/42) 0.87 (32/37)
Delayed enhancing rim 0.55 (23/42) 0.83 (31/37)
Figure 2. A 41-year-old man with hepatitis C and cirrhosis.
(a) T1-weighted volumetric 3D fat-suppressed spoiled gradi-
ent echo MR image (TR/TE, 4–6/1.2 msec flip angle 12) in
the arterial phase demonstrating a small enhancing nodule
(arrow). (b) MR images obtained in the extracellular phase
show no hypointensity. However, at transplant this lesion
was confirmed to be HCC.
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incidence, more specific criteria for characterization of
these nodules as HCC is needed.
Previous studies suggest that T2-W imaging does
not provide additional diagnostic value compared to
3D gadolinium-enhanced imaging (29–31) for the
diagnosis of HCC in the cirrhotic liver. Similar to other
studies (32,33), our results suggest that T2-W imag-
ing has better sensitivity in larger 2–5 cm lesions
(0.80, 25/31) but decreases with smaller HCC <2 cm
(0.53, 21/40).
As nodules progress to HCC and develop increasing
arterial blood supply, there is a simultaneous decrease
in their portal venous supply with resultant decreased
enhancement during venous and extracellular phases
Figure 3. A 63-year-old man with hepatitis C and cirrhosis. (a) T1-weighted volumetric 3D fat-suppressed spoiled gradient
echo MR image (TR/TE, 4–6/1.2 msec flip angle 12) in the arterial phase demonstrating a small enhancing nodule (arrow).
(b) MR images obtained in the extracellular phase show hypointensity and a peripheral enhancing rim. However, biopsy fol-
low-up yielded chronic fibrosis. The perception of the capsule may be secondary to delayed enhancing fibrosis in the sur-
rounding liver parenchyma. (c,d) A 28-month follow-up MRI demonstrates minimal change in lesion size.
Table 2
P-values of All Main Imaging Features of HCC Fitted in the GEE
Model to Predict HCC
Imaging variable P-value
Size (<2 cm, 2 cm) 0.066
Delayed hypointensity 0.383




*P-value equal to or less than 0.05 is statistically significant. Sensi-
tivity: 0.732 (52/71) 95% CI (0.614, 0.831); specificity: 0.628
(27/42) 95% CI (0.480, 0.785).
Table 3
P-values of Main Imaging Features and Their Interactions Fitted in
the GEE Model to Predict HCC
Imaging variables P-value




Size  hypointensity 0.987
Size  rim <2  1016*
Size xT2-weighted hyperintensity 0.633
*P-value equal to or less than 0.05 is statistically significant. Cross-
validated sensitivity and specificity for this model: Sensitivity: 0.803
(57/71) 95% CI (0.691, 0.888); specificity: 0.619 (26/42) 95% CI
(0.456, 0.764).
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(34). Delayed hypointensity has been shown to be
highly predictive of HCC. Marrero et al (16) showed
sensitivity of 80% and specificity of 95% of delayed
hypointensity for HCC in arterially enhancing nodules
<2 cm, while Burrel et al (7) found arterial enhance-
ment with delayed hypointensity to be 89% sensitive
for HCC in 1–2 cm nodules. In our study, delayed
hypointensity of arterially enhancing lesions <2 cm as
an indicator for HCC was less sensitive at 41% (17/
42) but demonstrated good specificity of 87% (32/37).
For HCC measuring 2–5 cm, delayed hypointensity
had a sensitivity of 72% (23/32) and specificity of
80% (4/5). The lower sensitivity in this study com-
pared to previous work may be secondary to patient
inclusion criteria. We included patients with biopsy
and long-term MRI follow-up compared to Burrel et al
(7), who included only explant patients, many of
whom had known concomitant HCC possibly increas-
ing the likelihood that visualized lesion was HCC. A
study by Yu et al (35) which also included biopsy and
MRI follow-up reported similar results for delayed
hypointensity in HCC 2 cm with sensitivity of 43%
and specificity of 89%.
In all, 34 of 74 HCC in our study did not demon-
strate delayed hypointensity including 25/42 <2 cm
and 9/32 2–5 cm HCCs. This likely relates to internal
histological variations and possibly residual portal ve-
nous supply (20,34). Also, as portal venules have
been suggested as the main drainage of HCC (36),
immature portal venous drainage may prevent obser-
vation of delayed hypointensity.
The presence of a tumor capsule has been associ-
ated with the peripheral enhancing rim of HCC
(14,17,34,35). This capsule is histologically composed
of an inner layer of fibrous tissue and an outer layer
of compressed vessels (17,34). The fibrous tissue will
retain contrast longer than surrounding parenchyma,
resulting in a delayed enhancing rim (35). This
delayed rim enhancement has been shown to be
highly specific for HCC in arterially enhancing lesions
(14). A transient rim of enhancement in the venous
phase, referred to as the ‘‘corona of HCC,’’ is another
possible cause for the peripheral enhancing rim. This
is due to enhancement of compressed hepatic sinu-
soids surrounding the tumor. These sinusoids receive
the portal venous drainage of HCC (36).
Comparing delayed hypointensity and delayed
enhancing rim, our data suggest that the presence of
a peripheral rim has slightly higher sensitivity but
essentially similar specificity for the diagnosis of HCC
of all sizes. Currently the AASLD emphasizes delayed
hypointensity in the diagnosis of HCC, recommending
that for 1–2 cm arterial hypervascular lesions, if hypo-
intensity in the portal venous or delayed phase is con-
firmed on two dynamic studies, either CT scan, con-
trast ultrasound, or MRI with contrast, the lesion can
be treated as HCC without pathological confirmation
(15). However, our study shows that the delayed
enhancing rim is a better predictor of HCC both as a
main feature or in combination with size 2 cm as
compared with delayed hypointensity.
Overall specificity of both delayed hypointensity and
delayed enhancing rim was (0.86, 37/42) in this
study. As biopsy verification of three of the lesions
demonstrating hypointensity and two of the lesions
with delayed enhancing rim yielded fibrosis, regenera-
tive nodule or dysplastic nodule, sampling error could
have increased the false-positive results. Also, as sug-
gested by Yu et al (35), underlying fibrosis could also
contribute to a false-positive rate since delayed hypo-
intensity and delayed enhancing rim may be overesti-
mated due to visual misperception caused by delayed
enhancement of surrounding fibrotic parenchyma
(Fig. 3a,b).
The study has several limitations. The study design
is retrospective. The explanted livers were not always
cut with the radiologist physically present but were
always compared to the MRI report. Selection bias
may have been introduced, as only lesions/patients
suspicious for HCC were more likely be followed and
hence be included in the study. As mentioned above,
sampling error could have occurred in benign lesions
verified by biopsy, leading to a false-negative diagno-
sis of HCC. Also, evaluation of imaging features was
done qualitatively, and readers may have different
thresholds for these features.
In conclusion, in arterially enhancing nodules of all
sizes, delayed hypointensity improves the specificity
of diagnosis of HCC but is frequently absent in very
small HCC (<2 cm). Moreover, the presence of a
delayed enhancing rim, irrespective of the presence of
delayed hypointensity, is a strong predictor of HCC.
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